Brain metastasis: Recent treatment modalities and future‑perspectives (Review)
- Authors:
- Atsuto Katano
- Hideomi Yamashita
-
Affiliations: Department of Radiology, University of Tokyo Hospital, Bunkyo, Tokyo 113‑8655, Japan - Published online on: April 29, 2022 https://doi.org/10.3892/ol.2022.13311
- Article Number: 191
This article is mentioned in:
Abstract
Nayak L, Lee EQ and Wen PY: Epidemiology of brain metastases. Curr Oncol Rep. 14:48–54. 2012. View Article : Google Scholar : PubMed/NCBI | |
Lin X and DeAngelis LM: Treatment of brain metastases. J Clin Oncol. 33:3475–3484. 2015. View Article : Google Scholar | |
Sacks P and Rahman M: Epidemiology of brain metastases. Neurosurg Clin N Am. 31:481–488. 2020. View Article : Google Scholar : PubMed/NCBI | |
Bhambhvani HP, Granucci M, Rodrigues A, Kakusa BW and Hayden Gephart M: The primary sites leading to brain metastases: Shifting trends at a tertiary care center. J Clin Neurosci. 80:121–124. 2020. View Article : Google Scholar | |
Ostrom QT, Wright CH and Barnholtz-Sloan JS: Brain metastases: Epidemiology. Handb Clin Neurol. 149:27–42. 2018. View Article : Google Scholar | |
Tabouret E, Chinot O, Metellus P, Tallet A, Viens P and Gonçalves A: Recent trends in epidemiology of brain metastases: An overview. Anticancer Res. 32:4655–4662. 2012.PubMed/NCBI | |
Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T and Ho C: Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. Curr Oncol. 24:228–233. 2017. View Article : Google Scholar | |
Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, et al: Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 17:935–944. 2006. View Article : Google Scholar | |
Arvanitis CD, Ferraro GB and Jain RK: The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 20:26–41. 2020. View Article : Google Scholar : PubMed/NCBI | |
McTyre E, Scott J and Chinnaiyan P: Whole brain radiotherapy for brain metastasis. Surg Neurol Int. 4 (Suppl 4):S236–S244. 2013. View Article : Google Scholar | |
Mehta SR, Suhag V, Semwal M and Sharma N: Radiotherapy: Basic concepts and recent advances. Med J Armed Forces India. 66:158–162. 2010. View Article : Google Scholar | |
Gelband H, Jha P, Sankaranarayanan R and Horton S: Cancer: Disease Control Priorities. Third Edition. (Volume 3). The International Bank for Reconstruction and Development/The World Bank; Washington, D.C.: 2015 | |
Xing L, Thorndyke B, Schreibmann E, Yang Y, Li TF, Kim GY, Luxton G and Koong A: Overview of image-guided radiation therapy. Med Dosim. 31:91–112. 2006. View Article : Google Scholar : PubMed/NCBI | |
Otto K: Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 35:310–317. 2008. View Article : Google Scholar : PubMed/NCBI | |
Sapkaroski D, Osborne C and Knight KA: A review of stereotactic body radiotherapy-is volumetric modulated arc therapy the answer? J Med Radiat Sci. 62:142–151. 2015. View Article : Google Scholar | |
DeAngelis LM, Delattre JY and Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology. 39:789–796. 1989. View Article : Google Scholar : PubMed/NCBI | |
Ali FS, Arevalo O, Zorofchian S, Patrizz A, Riascos R, Tandon N, Blanco A, Ballester LY and Esquenazi Y: Cerebral radiation necrosis: Incidence, pathogenesis, diagnostic challenges, and future opportunities. Curr Oncol Rep. 21:662019. View Article : Google Scholar : PubMed/NCBI | |
Kim JM, Miller JA, Kotecha R, Xiao R, Juloori A, Ward MC, Ahluwalia MS, Mohammadi AM, Peereboom DM, Murphy ES, et al: The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol. 133:357–368. 2017. View Article : Google Scholar | |
Donovan EK, Parpia S and Greenspoon JN: Incidence of radionecrosis in single-fraction radiosurgery compared with fractionated radiotherapy in the treatment of brain metastasis. Curr Oncol. 26:e328–e333. 2019. View Article : Google Scholar | |
Vellayappan BA, McGranahan T, Graber J, Taylor L, Venur V, Ellenbogen R, Sloan AE, Redmond KJ, Foote M, Chao ST, et al: Radiation necrosis from stereotactic radiosurgery-how do we mitigate? Curr Treat Options Oncol. 22:572021. View Article : Google Scholar | |
Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Romano A and Enrici RM: Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radionecrosis. Radiat Oncol. 6:482011. View Article : Google Scholar | |
Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH, Yang TJ, Rosenblum MK, Ballangrud Å, Young RJ, et al: Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol. 125:149–156. 2015. View Article : Google Scholar | |
Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J and Farnan N: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 47:291–298. 2000. View Article : Google Scholar : PubMed/NCBI | |
Loo M, Clavier JB, Attal Khalifa J, Moyal E and Khalifa J: Dose-Response effect and dose-toxicity in stereotactic radiotherapy for brain metastases: A review. Cancers (Basel). 13:60862021. View Article : Google Scholar : PubMed/NCBI | |
Putz F, Weissmann T, Oft D, Schmidt MA, Roesch J, Siavooshhaghighi H, Filimonova I, Schmitter C, Mengling V, Bert C, et al: FSRT vs. SRS in brain metastases-differences in local control and radiation Necrosis-A volumetric study. Front Oncol. 10:5591932020. View Article : Google Scholar | |
Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG II, Deming R, Burri SH, et al: Effect of radiosurgery alone vs. radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA. 316:401–409. 2016. View Article : Google Scholar : PubMed/NCBI | |
Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, et al: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol. 15:387–395. 2014. View Article : Google Scholar | |
Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA and Young B: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 280:1485–1489. 1998. View Article : Google Scholar : PubMed/NCBI | |
Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS and Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 322:494–500. 1990. View Article : Google Scholar : PubMed/NCBI | |
Kayama T, Sato S, Sakurada K, Mizusawa J, Nishikawa R, Narita Y, Sumi M, Miyakita Y, Kumabe T, Sonoda Y, et al: Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): A phase III, noninferiority, randomized controlled trial. J Clin Oncol. JCO20187861862018. | |
Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, et al: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): A multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 18:1049–1060. 2017. View Article : Google Scholar | |
Kępka L, Tyc-Szczepaniak D, Bujko K, Olszyna-Serementa M, Michalski W, Sprawka A, Trąbska-Kluch B, Komosińska K, Wasilewska-Teśluk E and Czeremszyńska B: Stereotactic radiotherapy of the tumor bed compared to whole brain radiotherapy after surgery of single brain metastasis: Results from a randomized trial. Radiother Oncol. 121:217–224. 2016. View Article : Google Scholar | |
Randall Patrinely J Jr, Funck-Brentano E, Nguyen K, Rapisuwon S, Salem JE, Gibney GT, Carlino M and Johnson DB: A multicenter analysis of immune checkpoint inhibitors as adjuvant therapy following treatment of isolated brain metastasis. Oncologist. 26:e505–e507. 2021. View Article : Google Scholar | |
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, et al: Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 40:492–516. 2022. View Article : Google Scholar | |
Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, et al: Evaluation of first-line radiosurgery vs. whole-brain radiotherapy for small cell lung cancer brain metastases: The FIRE-SCLC Cohort Study. JAMA Oncol. 6:1028–1037. 2020. View Article : Google Scholar | |
Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H and Aisner J: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 341:476–484. 1999. View Article : Google Scholar | |
Arriagada R, Le Chevalier T, Borie F, Rivière A, Chomy P, Monnet I, Tardivon A, Viader F, Tarayre M and Benhamou S: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 87:183–190. 1995. View Article : Google Scholar | |
Yin X, Yan D, Qiu M, Huang L and Yan SX: Prophylactic cranial irradiation in small cell lung cancer: A systematic review and meta-analysis. BMC Cancer. 19:952019. View Article : Google Scholar : PubMed/NCBI | |
Pezzi TA, Fang P, Gjyshi O, Feng L, Liu S, Komaki R and Lin SH: Rates of overall survival and intracranial control in the magnetic resonance imaging Era for patients with limited-stage small cell lung cancer with and without prophylactic cranial irradiation. JAMA Netw Open. 3:e2019292020. View Article : Google Scholar : PubMed/NCBI | |
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T and Yang S: Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduct Target Ther. 6:2012021. View Article : Google Scholar : PubMed/NCBI | |
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 382:41–50. 2020. View Article : Google Scholar : PubMed/NCBI | |
Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T and Sagara H: Comparative efficacy and safety of lorlatinib and alectinib for ALK-Rearrangement positive advanced non-small cell lung cancer in asian and non-asian patients: A systematic review and network meta-analysis. Cancers (Basel). 13:37042021. View Article : Google Scholar : PubMed/NCBI | |
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, et al: First-Line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 383:2018–2029. 2020. View Article : Google Scholar : PubMed/NCBI | |
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, et al: Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 23:122–133. 2021. View Article : Google Scholar | |
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et al: Tucatinib, trastuzumab, and capecitabine for HER2-Positive metastatic breast cancer. N Engl J Med. 382:597–609. 2020. View Article : Google Scholar : PubMed/NCBI | |
Huang PW and Chang JW: Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J. 42:299–306. 2019. View Article : Google Scholar : PubMed/NCBI | |
Corroyer-Dulmont A, Jaudet C, Frelin AM, Fantin J, Weyts K, Vallis KA, Falzone N, Sibson NR, Chérel M, Kraeber-Bodéré F, et al: Radioimmunotherapy for brain metastases: The potential for inflammation as a target of choice. Front Oncol. 11:7145142021. View Article : Google Scholar | |
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, et al: Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17:976–983. 2016. View Article : Google Scholar | |
Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, et al: Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): Final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 22:1692–1704. 2021. View Article : Google Scholar | |
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 37:745–751. 1997. View Article : Google Scholar : PubMed/NCBI | |
Schag CC, Heinrich RL and Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol. 2:187–193. 1984. View Article : Google Scholar | |
Sperduto PW, Berkey B, Gaspar LE, Mehta M and Curran W: A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 70:510–514. 2008. View Article : Google Scholar : PubMed/NCBI | |
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 30:419–425. 2012. View Article : Google Scholar | |
Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, et al: Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 3:827–831. 2017. View Article : Google Scholar | |
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, et al: Beyond an updated graded prognostic assessment (Breast GPA): A prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol Phys. 107:334–343. 2020. View Article : Google Scholar : PubMed/NCBI | |
Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D, Holt T, et al: Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial. Lancet. 388:2004–2014. 2016. View Article : Google Scholar | |
Lin B, Gao F, Yang Y, Wu D, Zhang Y, Feng G, Dai T and Du X: FLASH radiotherapy: History and future. Front Oncol. 11:6444002021. View Article : Google Scholar | |
Montay-Gruel P, Acharya MM, Petersson K, Alikhani L, Yakkala C, Allen BD, Ollivier J, Petit B, Jorge PG, Syage AR, et al: Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species. Proc Natl Acad Sci USA. 116:10943–10951. 2019. View Article : Google Scholar : PubMed/NCBI | |
Shepard MJ, Xu Z, Donahue J, Eluvathingal Muttikkal TJ, Cordeiro D, Hansen L, Mohammed N, Gentzler RD, Larner J, Fadul CE and Sheehan JP: Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: A matched cohort study. J Neurosurg. 133:685–692. 2019. View Article : Google Scholar |